Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot Password? Reset your password

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login (Shibboleth)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Table of Contents
Vol. 35, No. 1, 2012
Issue release date: January 2012
Section title: Original Paper
Kidney Blood Press Res 2012;35:58–67
(DOI:10.1159/000330496)

Renal Anemia Treatment with ESA in Hemodialysis Patients in Relation to Early versus Late Referral in Everyday Clinical Practice in Central and Eastern European Countries: Baseline Data

Malyszko J.a · Drozdz M.b · Zolkiewicz A.c · Rutkowski B.d
aDepartment of Nephrology and Transplantology, Medical University, Bialystok, bDepartment of Nephrology, Collegium Medicum, Jagiellonian University, Cracow, cRoche Pharmaceutical Company, Warsaw, and dDepartment of Nephrology, Transplantology and Internal Diseases, Medical University, Gdansk, Poland
email Corresponding Author

Prof. Jolanta Malyszko

Department of Nephrology and Transplantology, Medical University

Zurawia 14

PL–15-540 Bialystok (Poland)

Tel. +48 85 740 9464, E-Mail jolmal@poczta.onet.pl


References

  1. National Kidney Foundation (NKF) Kidney Disease Outcome Quality Initiative (K/DOQI) Advisory Board: K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis 2002;39(suppl 2):S1–S246.
  2. Eschbach JW, Adamson JW: Anaemia of end-stage renal disease (ESRD). Kidney Int 1985;28:1–5.
  3. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE: The impact of anaemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 1996;28:53–61.
  4. Portoles J, Torralbo A, Martin P, Rodrigo J, Herrero JA, Barrientos A: Cardiovascular effects of recombinant human erythropoietin in predialysis patients. Am J Kidney Dis 1997;29:541–548.
  5. Eschbach JW, Aquiling T, Haley NR, Fan MH, Blagg CR: The long-term effects of recombinant human erythropoietin on the cardiovascular system. Clin Nephrol 1992;38(suppl 1):S98–S103.
    External Resources
  6. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D: CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085–2098.
  7. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A, CREATE Investigators: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006;355:2071–2084.
  8. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R: TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009;361:2019–2032.
  9. McClellan WM, Flanders WD, Gutman RA: Variable mortality rates among dialysis treatment centres. Ann Intern Med 1992;117:332–336.
  10. Hulbert-Shearon TE, Loos E, Ashby VB, Port FK, Wolfe RA: USRDS 1999 Unit-Specific Reports for Dialysis Patients: A Summary. University of Michigan, Ann Arbor, 1999.
  11. Wiecek A, Covic A, Locatelli F, Macdougall IC, on behalf of the ORAMA Study Group: Renal anaemia: comparing current eastern and western European management practice (ORAMA). Ren Fail 2008;30:267–276.
    External Resources
  12. Rath T, Mactier RA, Weinreich T, Scherhag AW, GAIN Investigators: Effectiveness and safety of recombinant human erythropoietin beta in maintaining common haemoglobin targets in routine clinical practice in Europe: the GAIN study. Curr Med Res Opin 2009;25:961–970.
  13. European Survey on Anaemia Management (ESAM). Nephrol Dial Transplant 1999;14(suppl 5):1–76.
  14. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31–41.
  15. Modification of Diet in Renal Disease Study Group: Creatinine filtration, secretion and excretion during progressive renal disease. Kidney Int 1989;36:S73–S80.
    External Resources
  16. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J, CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration): A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604–612.
  17. Collins AJ, Roberts TL, St Peter WL, Chen SC, Ebben J, Constantini E: United States Renal Data System assessment of the impact of the National Kidney Foundation – Dialysis Outcomes Quality Initiative guidelines. Am J Kidney Dis 2002;39:784–795.
  18. National Kidney Foundation: NKF-K/DOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults. Am J Kidney Dis 2006;47(suppl 3):16–85.
  19. National Kidney Foundation: NKF-KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis. 2007;50:471–530.
  20. Valderrabano F, Horl WH, Macdougall IC, Rossert J, Rutkowski B, Wauters JP: PRE-dialysis survey on anaemia management. Nephrol Dial Transplant 2003;18:89–100.
  21. Jacobs C, Frei D, Perkins AC: Results of the European Survey on Anaemia Management 2003 (ESAM 2003): current status of anaemia management in dialysis patients, factors affecting epoetin dosage and changes in anaemia management over the last 5 years. Nephrol Dial Transplant 2005;20(suppl 3): 3–24.
  22. Valderrabano F, Horl WH, Jacobs C, et al: European best practice guidelines 1–4: evaluating anaemia and initiating treatment. Nephrol Dial Transplant 2000;15(suppl 4): 8–14.
    External Resources
  23. Pisoni RL, Bragg-Gresham JL, Young EW, et al: Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004;44:94–111.
  24. Locatelli F, Pisoni RL, Combe C, et al: Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2004;19:121–132.
  25. Rayner HC, Pisoni RL, Bommer J, Canaud B, Hecking E, Locatelli F, Piera L, Bragg-Gresham JL, Feldman HI, Goodkin DA, Gillespie B, Wolfe RA, Held PJ, Port FK: Mortality and hospitalization in haemodialysis patients in five European countries: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2004;19:108–120.
  26. Locatelli F, Aljama P, Canaud B, et al: On behalf of the Anaemia Working Group of European Renal Best Practice (ERBP). Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to Reduce Cardiovascular Events with Aranesp(R) Therapy (TREAT) Study. Nephrol Dial Transplant 2010;25:2846–2850.
  27. Locatelli F, Covic A, Macdougall IC, Wiecek A, on behalf of the ORAMA Study Group: ORAMA: a study to investigate EBPG impact on renal anaemia – design and baseline data. J Nephrol 2008;21:592–602.